Abbott Laboratories
ABT
$84.90
+1.28%
Abbott Laboratories is a diversified global healthcare company operating in the medical devices, diagnostics, nutritional products, and established pharmaceuticals industries. It is a market leader with a strong competitive identity built on a portfolio of essential, life-sustaining products like continuous glucose monitors, cardiovascular devices, and infant formula, deriving roughly 60% of its sales internationally. The current investor narrative is dominated by a significant stock price decline following a cut to its annual profit guidance for 2026, which has overshadowed a recent earnings beat and raised concerns about near-term headwinds, juxtaposed against its long-term reputation for stability and a 54-year history of dividend growth.…
ABT
Abbott Laboratories
$84.90
Related headlines
ABT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $110.37 and implied upside of +30.0% versus the current price.
Average Target
$110.37
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$68 - $110
Analyst target range
Analyst coverage for Abbott is robust, with 9 analysts providing estimates, and institutional ratings data shows a unanimously bullish sentiment with recent actions from firms like Citigroup, Barclays, and RBC Capital all maintaining Buy, Overweight, or Outperform ratings; however, a consensus price target is not provided in the data, so the implied upside or downside cannot be calculated from the given inputs. The range of analyst estimates shows high conviction in future earnings, with an estimated EPS range for the coming period of $8.01 to $8.43 around an average of $8.36; the tight clustering of these EPS estimates suggests strong agreement on the company's fundamental earnings power, but the lack of price targets limits insight into the expected trading range. The recent guidance cut has clearly impacted the stock price, but the maintained bullish ratings from major firms indicate analysts view the weakness as a temporary setback rather than a permanent impairment to the long-term investment thesis.
Bulls vs Bears: ABT Investment Factors
The investment debate for Abbott Laboratories is a classic clash between valuation and momentum. The bear case, driven by the severe price decline, growth deceleration, and guidance cut, currently holds stronger near-term evidence, as reflected in the stock's persistent downtrend and deep underperformance. However, the bull case presents a compelling long-term value proposition anchored in the company's pristine balance sheet, strong cash flow, and a forward P/E that prices in substantial pessimism. The single most important tension is whether the company's robust fundamental health and analyst-expected earnings recovery ($8.36 EPS) can overcome the powerful negative momentum and growth concerns that have driven the stock to multi-year lows. The resolution of this tension hinges on the next few quarters of execution against the lowered guidance.
Bullish
- Strong Financial Health & Cash Flow: Abbott generates robust annual free cash flow of $7.4 billion (TTM) and maintains a conservative debt-to-equity ratio of 0.29. This fortress balance sheet provides a significant margin of safety, funding the dividend, buybacks, and strategic acquisitions like Exact Sciences without financial strain.
- Attractive Forward Valuation: The stock trades at a forward P/E of 14.75x, a steep discount to its trailing P/E of 33.55x. This forward multiple implies the market has already priced in significant pessimism and expects a meaningful earnings recovery, offering a compelling entry point for a healthcare leader.
- Unanimous Analyst Bullishness: Despite the recent guidance cut, all 9 covering analysts maintain Buy-equivalent ratings, with high conviction in future EPS averaging $8.36. This consensus suggests the professional investment community views the current weakness as a temporary setback, not a structural decline.
- Deeply Oversold Technical Condition: The stock is down 31.65% over the past year and is trading just 0.36% above its 52-week low of $89.14. This extreme oversold condition, with a 1-month relative strength of -22.60 against the S&P 500, indicates excessive pessimism and sets up for a potential technical rebound.
Bearish
- Severe Growth Deceleration & Guidance Cut: Q4 revenue grew only 4.4% YoY, signaling a significant slowdown from prior periods. The recent cut to 2026 profit guidance, which overshadowed an earnings beat, is the primary catalyst for the stock's 31.65% annual decline and raises serious questions about near-term earnings power.
- Elevated Trailing Valuation vs. Slowing Growth: A trailing P/E of 33.55x is historically high for Abbott and appears stretched given the current 4.4% revenue growth rate. This premium valuation leaves the stock vulnerable to further multiple compression if earnings growth fails to re-accelerate as anticipated.
- Persistent Negative Momentum & Underperformance: The stock has underperformed the S&P 500 by over 60 percentage points in the past year. The downtrend is severe and sustained, with the stock down 18.15% over the past three months, indicating the market is pricing in a prolonged period of challenges, not a quick recovery.
- Margin Pressure Risk: While Q4 operating margin was 19.6%, the full-year guidance cut explicitly signals margin pressure ahead. With revenue growth slowing, the company may struggle to maintain its historically high profitability, directly impacting the earnings recovery priced into the forward P/E.
ABT Technical Analysis
The prevailing price trend for Abbott Laboratories is a pronounced and sustained downtrend, with the stock down 31.65% over the past year. As of the latest close at $89.46, the stock is trading at the very bottom of its 52-week range, just 0.36% above its 52-week low of $89.135, indicating the stock is deeply oversold and potentially at a value inflection point, though it also signals severe negative momentum and investor pessimism. Recent momentum remains sharply negative, with the stock down 12.62% over the past month and 18.15% over the past three months, which aligns with and accelerates the longer-term downtrend; this persistent selling pressure, highlighted by a 1-month relative strength of -22.60 against the S&P 500, suggests the negative guidance cut has catalyzed a sustained re-rating rather than a temporary pullback. Key technical support is firmly established at the 52-week low of $89.135, with resistance far above at the 52-week high of $139.06; a breakdown below the $89 support level could trigger further technical selling, while any recovery would need to overcome significant overhead supply. The stock's beta of 0.78 indicates it has been 22% less volatile than the broader market during this downturn, which is atypical for a stock in such a steep decline and may reflect its perceived defensive qualities and strong balance sheet.
Beta
0.65
0.65x market volatility
Max Drawdown
-40.2%
Largest decline past year
52-Week Range
$82-$139
Price range past year
Annual Return
-34.0%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | -16.0% | +7.7% |
| 3m | -24.7% | +9.7% |
| 6m | -35.0% | +11.3% |
| 1y | -34.0% | +27.3% |
| ytd | -31.6% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $11.46 billion representing a 4.4% year-over-year increase; however, the multi-quarter trend shows revenue deceleration from higher growth rates in prior periods, with sequential quarterly revenue in 2025 fluctuating between $10.36 billion and $11.46 billion, indicating a stabilization phase post-pandemic normalization, particularly in its diagnostics segment. The company remains solidly profitable, with Q4 2025 net income of $1.78 billion and a net margin of 15.5%, supported by a robust gross margin of 57.05%; profitability metrics have been stable, with operating margin at 19.6% for the quarter, though full-year margins are facing pressure as evidenced by the guidance cut, signaling potential compression ahead. Balance sheet and cash flow health is a key strength, with a conservative debt-to-equity ratio of 0.29, a strong current ratio of 1.58, and substantial annual free cash flow generation of $7.40 billion (TTM); this robust financial position, evidenced by an ROE of 12.5%, provides ample liquidity to fund the dividend, share repurchases, and strategic investments like the Exact Sciences acquisition without reliance on excessive external financing.
Quarterly Revenue
$11.5B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given Abbott's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 33.55x, while the forward P/E is significantly lower at 14.75x; this wide gap implies the market expects a substantial recovery in earnings growth, effectively pricing in the anticipated rebound from current depressed levels. Compared to sector averages, Abbott's trailing P/E of 33.55x and Price/Sales of 4.94x are not directly comparable without a provided industry benchmark, but the forward P/E of 14.75x appears reasonable for a healthcare leader if earnings estimates are achievable, suggesting the market has already discounted significant bad news. Historically, the current trailing P/E of 33.55x is above the stock's own recent historical range, which has fluctuated between approximately 5x (anomalous due to a one-time tax benefit in Q4 2024) and 46x over the past several years; trading near the higher end of its normalized band suggests the market is still pricing in a premium for its quality and growth, but it also indicates limited multiple expansion potential unless earnings accelerate meaningfully.
PE
33.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on earnings visibility and margin sustainability. The recent guidance cut for 2026 profit is the paramount risk, indicating management sees headwinds that could pressure the 15.5% net margin. Revenue growth has decelerated to 4.4% YoY, and with 60% of sales international, the company faces foreign exchange and geopolitical volatility. While the strong balance sheet (Debt/Equity 0.29) mitigates solvency risk, the key financial risk is that earnings fail to rebound to the analyst-consensus $8.36, invalidating the attractive forward P/E thesis.
Market & Competitive Risks are elevated due to valuation compression. The stock's trailing P/E of 33.55x is high relative to its current growth rate, making it susceptible to de-rating if growth stalls further. Its beta of 0.78 indicates it has been less volatile than the market, but the 31.65% annual decline shows it carries significant idiosyncratic risk from company-specific guidance misses. Competitive pressures in key markets like diabetes care (continuous glucose monitors) and diagnostics could intensify, while the Exact Sciences acquisition carries integration execution risk. The recent news cycle is dominated by the guidance cut, reinforcing negative sentiment.
Worst-Case Scenario involves a failure to stabilize earnings, leading to a cascade of analyst downgrades and a full valuation re-rate towards a market-average multiple. If revenue growth stalls and margins compress further, the forward EPS estimates could be cut, making the current forward P/E of 14.75x misleadingly cheap. In this adverse scenario, the stock could retest and break its 52-week low of $89.14, potentially falling towards a bear-case P/E of 12-13x on lowered earnings, implying a downside of 15-20% from the current $89.46 price. The maximum drawdown of -35.21% over the past year provides a historical benchmark for severe loss potential.